Table 1.

Study measures.

Measure			Items		Baseline		Weekly		3 months		6 and 9 months
Baseline measures
	Demographic information, MOUDa information, and clinical characteristics of chronic pain			✓
	MINIb International Neuropsychological Interview [59]	Interview		✓
	Graded Chronic Pain Scale–Revised (frequency, severity, and impact of pain) [53]	6		✓
	Addiction Severity Index [60]	Interview		✓				✓		✓
Primary outcome (in 3 months)
	Buprenorphine retention	none		✓				✓		✓
Secondary outcome measures
	PROMISc Pain Interference 6a [61]	6		✓				✓		✓
	MOUD Adherenced	None		✓		✓		✓		✓
	The Craving Scale [62]	3		✓				✓		✓
	Timeline Follow-Back Substance Use Calendar [63]	Interview		✓		✓		✓		✓
	Urine toxicology	None		✓		✓		✓		✓
	NRSe Pain Intensity Rating [64]	1		✓				✓		✓
	PROMIS Physical Function 6b [65]	7		✓				✓		✓
	Pain Catastrophizing Scale [66]	14		✓				✓		✓
	Pain Self-Efficacy Questionnaire [67]	11		✓				✓		✓
	PROMIS Sleep Disturbance 6a and Duration [68]	9		✓				✓		✓
Other measures
	Brief Symptom Inventory [69]	18		✓				✓		✓
	Cold pressor task	None		✓				✓		✓
	PHQ-4f (brief screen for anxiety and depression) [70]	4		✓				✓		✓
	Program and Client Cost-Substance Abuse Treatment (treatment use) [71]	Interview		✓				✓		✓
	IMPACTg engagement data (IMPACT+TAUh only)	None				✓

^aMOUD: medications for opioid use disorder.

^bMINI: Mini-International Neuropsychiatric Interview.

^cPROMIS: Patient Reported Outcomes Measurement Information System.

^dAdherence will be assessed with the Timeline Followback for daily MOUD use for the previous week, clinic dispensing records, and urine toxicology screen for buprenorphine or methadone collected at each weekly assessment visit.

^eNRS: Numerical Rating Scale.

^fPHQ-4: Patient Health Questionnaire-4.

^gIMPACT: Integrating the Management of Pain and Addiction via Collaborative Treatment.

^hTAU: treatment as usual.